MEMaryam Emadzadeh

Maryam Emadzadeh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Maryam Emadzadeh has a total of 240 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The Value of Left Atrial Strain and Strain Rate for Prediction of Early Postoperative Atrial Fibrillation Following Isolated Off‐Pump Coronary Artery Bypass Grafting in Low‐Risk Patients

    by Leila Bigdelu, Ali Azari, Ossama Maadarani, Somaye Bakefayat, Negar Ebrahimi, Maryam Emadzadeh

    Background: Following coronary artery bypass grafting (CABG) surgery, postoperative atrial fibrillation (POAF) is a prevalent arrhythmia. Prior research has demonstrated a paucity of reliable approaches to predict early POAF after CABG, particularly in low‐risk subjects. The present investigation proposed to assess how effectively left atrial (LA) strain and LA strain rate predict early POAF after isolated off‐pump CABG (OPCAB) in low‐risk individuals. Methods: One hundred and twenty‐three low‐risk subjects with sinus rhythm who underwent isolated OPCAB were assessed in this prospective research. The velocity vector imaging (VVI) method was utilized to measure LA strain and LA strain rate. Subsequently, the patients were monitored post‐surgery for 1 week to assess whether early POAF had occurred. Results: In contrast to those who did not experience early POAF, individuals with early POAF showed significantly lower LA strain (21.25 vs. 37.59, p < 0.001), lower LA strain rate (1.37 vs. 2.73, p < 0.001), and higher left atrial volume index (LAVI) ( p < 0.001). A 1‐unit increase in LA strain was associated with a 33% decrease in the odds of early POAF (OR = 0.67, 95% CI: 0.50–0.89; p = 0.006). Conclusion: Preoperative left atrial strain measurements may serve as an effective predictor of early POAF in low‐risk patients after isolated OPCAB. Rather than treating all patients undergoing CABG, identifying the group at greater risk for early POAF may enable targeted prophylactic therapy.

  • Allergic fungal rhinosinusitis and its fungal species in Eastern Mediterranean: A systematic review

    by Mehraneh Movahedi Aliabadi, Mohammad Sharifi Sarasyabi, Reyhaneh Asoudeh, Keihan Mostafavi, Maryam Emadzadeh, Hossein Zarrinfar

  • Designing a machine learning model for predicting cardiovascular events using the triglyceride-glucose index: a cohort study

    by Hedieh Alimi, Vahid Mahdavizadeh, Majid Ghayour-Mobarhan, Susan Darroudi, Armin Doostparast, Maryam Emadzadeh, Habibollah Esmaily, Alireza Heidari-Bakavoli, Bahram Shahri, Parsa Seyed Hosseini, et al.


  • Open Access

    Treatment Outcomes of Lobular Granulomatous Mastitis: Impact of Hyperprolactinemia, Diabetes, and Erythema Nodosum—Insights From a 7‐Year Cohort Study

    by Mina AkbariRad, Fereshte Sheybani, Abdollah Firoozi, Samaneh Sajjadi, Maryam Emadzadeh, Marzieh Kazerani, Sajad Ataei Azimi, Mahdieh Mottaghi

    Background: This study presents our observations on the management and follow‐up of patients diagnosed with lobular granulomatous mastitis (LGM) in a cohort study. Additionally, characteristics associated with a longer disease course, as well as treatment challenges in patients with erythema nodosum, diabetes, and hyperprolactinemia, would be discussed. Methods: From 2015 to 2021, a total of 246 consecutive LGM patients referred to the internal medicine clinic of Ghaem teaching hospital, Mashhad, Iran, were enrolled. Regular assessments were conducted every 3 months until complete symptom resolution. Treatment responses were categorized into five groups: complete resolution, incomplete resolution, resolution with subsequent relapse, no significant improvement, and treatment cessation, with all data meticulously recorded. Telephone follow‐ups were conducted with all patients at the end of the study in December 2022. Results: A total of 156 episodes were analyzed. Prednisone was administered to 136 patients, while oral methotrexate (MTX) was prescribed to 48 cases. The median age of the cohort was 33 years (interquartile range [IQR], 29–38). Of those on prednisone, 57 (41.9%) achieved complete resolution, with 15 (11%) experiencing subsequent relapse, 33 (24.3%) showing no significant improvement, and 31 (19.9%) discontinuing treatment. Among the MTX recipients, 23 (47.9%) achieved complete resolution, while one showed incomplete resolution. Over the median follow‐up of five years (IQR, 4–6), 139 (89.1%) reported complete resolution, nine (5.8%) showed incomplete resolution, and 8 (5.1%) remained symptomatic. The median disease duration was 18 months (IQR, 7–36). Abscess formation during treatment correlated with prolonged disease duration ( p < 0.04), and higher plasma prolactin levels were associated with extended disease duration ( p = 0.001). However, the disease course did not significantly differ in diabetic cases or those with erythema nodosum compared to others. Conclusions: Although more than half of LGM patients experienced no significant improvement, recurrence, or discontinued treatment on prednisone or MTX, however, over a median follow‐up of 5 years, approximately 90% of LGM patients achieved complete resolution within a median course of 18 months. The presence of abscesses during treatment and elevated plasma prolactin levels was linked to longer disease duration.


  • Evaluation of the Efficacy of a Nanomicellar Formulation of Fat-Soluble Vitamins in Patients with Cystic Fibrosis: a Randomized Controlled Trial

    by Mahsa Soleimanzadeh, Hamid Reza Kianifar, Mahmoud Reza Jaafari, Saber Hakiminasab, Maryam Emadzadeh, Ali Jafarzadeh Esfahani, Saeedeh Talebi

  • Randomized trial of biopsy needle sandblasting in coaxial core-needle liver biopsy: no significant improvement in ultrasound visibility, pain, or tissue yield

    by Masoud Pezeshki Rad, Maryam Ghandhari, Armin Doostparast, Maryam Emadzadeh, Amir Hossein Khosronejad, Alireza Khazen

    Purpose Optimizing biopsy needle design could enhance procedural performance and patient comfort during core-needle liver biopsy (CNLB). This study aimed to compare a modified biopsy needle with a conventional one in terms of ultrasound visibility, patient-reported pain intensity, and diagnostic tissue yield. Methods In this randomized, triple-blind clinical trial, 70 adult patients scheduled for CNLB at Imam Reza Hospital (Mashhad, Iran) were enrolled and randomly assigned to either a conventional or modified needle group, both of which were commercially available. The modified needle was manufactured by doubling the sandblasting duration, which increased surface roughness and tip sharpness (2.74 to 5.28 Newtons). Pain intensity was measured using the Visual Analogue Scale (VAS) at four time points: during the procedure, 10 min after, 30 min after, and at discharge. The ultrasound visibility and the number of portal tracts in biopsy specimens were assessed independently. Patients requiring intravenous analgesics due to severe pain were excluded from further analysis. Results 33 participants in the conventional biopsy needle group and 34 in the modified biopsy needle group completed all evaluations. There were no significant differences between groups in terms of age (P = 0.85), sex (P = 0.38), biopsy indication (P = 0.50), ultrasound visibility (P = 0.12), pain intensity at any time point (P > 0.05), and the number of portal tracts in biopsy specimens (P = 0.74). Despite the non-significant differences, both groups demonstrated low pain scores. Conclusion The modified biopsy needle showed no significant improvement over the conventional needle regarding visibility, patient pain, and tissue adequacy. Therefore, the choice between biopsy needles remains a matter of clinical preference, user familiarity, and cost-effectiveness rather than significant differences in performance. Trial registration IRCT20250422065439N1.


  • The effect of betahistine on weight-related and metabolic measures in patients with schizophrenia treated with olanzapine and risperidone

    by Najmeh Abbasi Jannatabadi, Maryam Emadzadeh, Mohammad Reza Fayyazi Bordbar, Seyed Ahmad Mohajeri, Mahsa Nahidi

    Background: Drugs for psychosis can cause weight gain and metabolic disorders in schizophrenia. Given its partial agonistic activity at histamine receptors, betahistine could shape the effects of drugs for psychosis on weight gain and food intake. This study evaluates the effect of betahistine administration on anthropometric indices and symptoms of schizophrenia in schizophrenic patients. Methods: This randomized controlled trial was conducted on schizophrenic patients between 2020 and 2022. After stratification based on the type of treatment (olanzapine ( n = 28) or risperidone ( n = 28)), patients of each stratum were randomly divided into two groups (betahistine or placebo). The duration of the intervention was 12 weeks. Betahistine was started at 8 mg/day and gradually increased to 48 mg in 11 days. Anthropometric indices were measured monthly, while fasting blood glucose, lipid profile, TSH, and Positive and Negative Syndrome Scale (PANSS) were assessed at baseline and 12 weeks. Results: All anthropometric measures improved in patients receiving betahistine, except for increased waist circumference in those receiving olanzapine + betahistine. Triglyceride levels were significantly reduced in the olanzapine + betahistine subgroup compared to the placebo group (−12.14 ± 15.49 vs −0.28 ± 9.31; p = 0.021). Moreover, PANSS decreased significantly in all groups during the study, but the difference between groups was not significant. Conclusion: The addition of betahistine appears to be well tolerated and positively influences anthropometric indices. These findings suggest that betahistine may help mitigate some of the metabolic side effects of drugs for psychosis, although further research is needed to confirm these effects and to explore the optimal dosage. Trial registration number: IRCT20191223045870N1 in Iranian Registry of Clinical Trials (https://irct.behdasht.gov.ir/).

  • Comparison of microRNA-21 expression in bladder cancer tumor with normal-appearing adjacent tissue and healthy controls

    by Salman Soltani, Hamid Reza Rahimi, Mahdi Mottaghi, Mahmoud Tavakkoli, Maryam Emadzadeh, Atena Aghaee, Sajjad Sadeghpour, Hamidreza Ghorbani

    Background MicroRNAs (miR) regulate post-transcriptional gene expression with an established role in cancer development, angiogenesis, invasion, and metastasis. miR-21 is an oncogenic miR that targets p53 and promotes tumor development. We aim to assess mir-21 expression in bladder cancer (BCa) and compare it to grossly normal-appearing tumor-adjacent tissue and controls. Methods This case–control study was implemented from December 2019 to July 2021. We collected 72 specimens of 36 BCa cases (36 specimens of tumoral tissue and 36 specimens of grossly normal-appearing adjacent tissue) and nine specimens from 9 control participants. After total mRNA extraction, microRNA expression was evaluated by Stem-loop real-time RT-PCR. Results Among the 45 participants, the mean ages in the BCa (36 patients) and control groups (9 patients) were 58.46 ± 16.69 and 56.89 ± 14.92, respectively. The mean expression of miR-21 was 1.8 ± 1.5, 2.8 ± 1.2, and 1.0 ± 0.5 in tumoral tissue, tumor-adjacent grossly normal tissue, and control specimens, respectively. miR-21 expression was higher in tumoral and tumor-adjacent tissues than in controls, with smokers exhibiting significantly elevated levels across all groups (p = 0.037). Additionally, miR-21 expression was significantly higher in high-grade versus low-grade BCa tumors (p = 0.025), with tumoral tissue expression levels of 1.9 ± 1.2 and 1.5 ± 1.3, respectively, and tumor-adjacent tissue levels of 2.7 ± 1.2 and 1.95 ± 1.4, respectively. In the control group, older age was associated with reduced expression of miR-21, whereas in BCa patients, the expression of miR-21 increased with aging (p < 0.05). Conclusion miR-21 expression was higher in the tumor-adjacent tissue than in tumoral tissue and control specimens. The study recognizes certain limitations, such as a limited control group and possible sample loss, which might influence the strength and applicability of the findings.


  • A randomized trial on efficacy of purified cannabidiol on spasticity in multiple sclerosis patients with gait problems: first report in Iran

    by Pegah Mousavi, Maryam Emadzadeh, Bahar Karimikhoshnoudian, Mohammad Ali Sahraian, Mehran Ghaffari, Vahid Shaygannejad, Maryam Payere, Ava Baghaei, Aram Zabeti, Mohammadali Nahayati

    This study aims to assess the effectiveness of pure cannabidiol (CBD) in reducing spasticity in multiple sclerosis (MS) patients with spasticity-related walking difficulties. 49Forty-nine MS patients were randomly assigned to receive either CBD C2 oral drops (n = 24, initially 5 mg/day, increasing to 70 mg/day over 2 weeks, and 80 mg/day from the third week to the fourth week) or a placebo (n = 25) at Ghaem Hospital, Mashhad, Iran. After one 1 month of treatment, the timed 25-foot walk (T25-FW) test was conducted, and patients completed several questionnaires, including the Modified Fatigue Impact Scale (MFIS), Multiple Sclerosis Walking Scale (MSWS-12), Urinary Frequency, Pittsburgh Sleep Quality Index (PSQI), Beck Depression Inventory (BDI-II), and EuroQoL (EQ-5D).The duration of the T25-FW test decreased in both groups, but the reduction was significantly greater in the intervention group (IG) compared to the placebo group (PG) (p = 0.031). Both groups experienced a reduction in maximum pain after 1 month, with the IG showing a significantly higher decrease (p = 0.033). There was no significant difference in plasticity levels between the groups at baseline, 4, and 8 weeks. Results indicate that CBD does not significantly reduce spasticity severity in MS patients. However, the T25-FW test results showed a notable reduction in test duration.


  • A Comparative Study of Dexamethasone and Methylprednisolone in COVID-19 Patients: Clinical Outcomes and Inflammatory Markers

    by Alireza Ziaei Moghaddam, Mostafa Soleimani, Behnam Imani, Sepideh Hejazi, Mohammadhossein Taherynejad, Mona Kabiri, Maryam Emadzadeh, Sahar Ravanshad

    Background: The Coronavirus disease 2019 (COVID-19) pandemic, prompted by SARS-CoV-2, has created complicated health crises. An excessive inflammatory response and cytokine storm characterize severe COVID-19. Corticosteroids like dexamethasone and methylprednisolone are used for their anti-inflammatory effects, but comparisons of their efficacy are lacking. Objective: This study seeks to rigorously assess and contrast the effectiveness of dexamethasone and methylprednisolone in combating COVID-19 infections. Methods: This retrospective clinical study evaluates the effects of these two corticosteroids by reviewing the files of 500 hospitalized COVID-19 patients. The baseline characteristics of the patients, chest CT severity score, type of steroid prescription, duration of hospitalization and steroid prescription, dosage of corticosteroid therapy, their recovery status, hospital mortality, and specific disease severity-associated markers, such as lactate dehydrogenase (LDH), complete blood count (CBC), C-reactive protein (CRP), and Erythrocyte sedimentation rate (ESR) were collected and compared. Results: The study found no significant difference in most disease severity-associated markers between the two corticosteroid groups. However, lower mortality rates and shortened hospital stays were significantly associated with dexamethasone, especially in critical patient groups. A detailed analysis of inflammatory markers suggested minimal differences based on the type of corticosteroid used. Conclusion: The study indicates that dexamethasone may have some advantages in specific clinical outcomes. Further research needs to explore the mechanisms involved despite similar anti-inflammatory profiles.